Elevar Therapeutics and Relay Therapeutics Announce Exclusive Global Licensing Agreement for Lirafugratinib
Elevar Therapeutics and Relay Therapeutics Announce Exclusive Global Licensing Agreement for Lirafugratinib
12/03/24, 1:18 PM
Money
$500 million
Industry
biopharma
therapeutics
biotechnology
health care
Type
agreement
Elevar Therapeutics and Relay Therapeutics have announced an exclusive global licensing agreement for lirafugratinib (RLY-4008), a potential best-in-class FGFR2 inhibitor that has shown differentiated efficacy in FGFR2-driven cholangiocarcinoma and demonstrated durable responses across multiple other types of FGFR2-altered solid tumors. The agreement grants Elevar Therapeutics worldwide rights to develop and commercialize lirafugratinib.
Company Info
Additional Info
Elevar Therapeutics is a fully integrated biopharmaceutical company dedicated to elevating treatment outcomes for patients who have limited or inadequate therapeutic options. Relay Therapeutics is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies.